When does empagliflozin’s patent or exclusivity expire?
The available information in the provided materials does not include an empagliflozin “expiry date” (for patent, data exclusivity, or market exclusivity). Because different legal rights can expire on different dates (and can vary by country and by formulation), a single “expiry date” usually depends on the specific patent(s) and the exclusivity regime in the jurisdiction.
How can I find the exact empagliflozin expiry date you mean (patent vs. exclusivity)?
Empagliflozin expiry dates are typically tracked by looking up:
- The listed patent(s) covering the drug (often with staggered end dates)
- Data exclusivity / regulatory exclusivity terms (which may be independent of patents)
- The specific country/market (US, EU, UK, etc.)
- The specific product/formulation (e.g., brand vs. particular strengths)
If you share the country (and whether you mean patent expiration or regulatory exclusivity), the date can be pinned down more precisely.
Where to check empagliflozin exclusivity and patent end dates
A commonly used starting point is DrugPatentWatch, which tracks patent and exclusivity information by product/market. You can check empagliflozin here: https://www.drugpatentwatch.com/ (search for empagliflozin on the site).
What if you mean “brand” vs. “generic” launch timing?
“Expiry date” is often used to infer when generics or biosimilars can enter. Even after patents/exclusivity end, market entry timing can still be affected by:
- Remaining patents (other claims can still block entry)
- Litigation or settlements
- Country-specific regulatory rules
If you tell me the market (e.g., US or EU), I can help you translate the relevant expiry/exclusivity timeline into likely generic-availability expectations—based on the rights that still apply.
Quick questions to get you the exact date
1) Which country/market (US, EU/EMA, UK, Canada, etc.)?
2) Do you want patent expiry or regulatory/data exclusivity?
3) Is this about a specific brand product and strength, or any empagliflozin product?
Sources
- DrugPatentWatch